Top Markets
Coin of the day
Galera Therapeutics, Inc. Galera Therapeutics, Inc.

Galera Therapeutics, Inc.

GRTX
Pozycja w akcjach #33956
Galera Therapeutics, Inc. operates as a clinical-stage biopharmaceutical... Galera Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company, specializing in the creation and commercialization of therapies aimed at revolutionizing cancer radiotherapy. Its lead investigational drug, avasopasem manganese (GC4419), functions as a small molecule superoxide dismutase mimetic. This compound has successfully completed a Phase III clinical trial targeting severe oral mucositis induced by radiation therapy in head and neck cancer (HNC) patients. Furthermore, GC4419 is currently undergoing Phase IIa clinical trials for radiotherapy-induced esophagitis in lung cancer patients, as well as for HNC patients undergoing standard-of-care radiation treatment. The company is also progressing with GC4711, another superoxide dismutase mimetic candidate, which is in a Phase I/II clinical trial. This trial evaluates its combination with stereotactic body radiation therapy (SBRT) for individuals diagnosed with non-small cell lung cancer and locally advanced pancreatic cancer. Galera Therapeutics was founded in 2012 and maintains its headquarters in Malvern, Pennsylvania.
Cena akcji
$17.15
Ostatnia synchronizacja: 2026-08-03
Kapitalizacja rynkowa
$6.51M
Zmiana (1 dzień)
9.80%
Zmiana (1 rok)
289.77%
Kraj
US
Handel Galera Therapeutics, Inc. (GRTX)

Kategoria

Historia ceny akcji dla Galera Therapeutics, Inc. (GRTX)
Najwyższa cena zamknięcia: $17.15 dnia 2026-08-01

Najniższa cena zamknięcia: $2.54K dnia 2019-11-01
Historia cen akcji firmy Galera Therapeutics, Inc. od 2019 do 2026
Roczna wydajność ceny akcji
Rok Wydajność
2026 (TTM) 98.59%
2025 -26.18%
2024 -76.56%
2023 -91.44%
2022 -45.34%
2021 -73.46%
2020 -7.59%
2019 0.00%
Cena akcji podobnych firm lub konkurencji
Firma Cena akcji Zmiana 1r% Kraj
$517.18 32.51%
US
$857.76 31.47%
NL
$733.26 7.36%
CH
$1.07K -6.40%
KR
$257.99 13.97%
BE